

**COMPANY OVERVIEW**

BIOLIFE4D Corp. is a pioneering, development stage biotech company that plans to leverage current advances in life sciences and cardiac tissue engineering to build human hearts first for cardiotoxicity testing and then potentially for suitable implantation.

We plan to strategically position ourselves at the center of an unprecedented convergence of regenerative medicine, stem cell biology, additive manufacturing (3D printing), and computing technology – all having reached a level of maturity where we believe that commercially viable bioprinting solutions can be created through optimization, not invention. With BIOLIFE4D, a patient-specific, fully functioning heart may be created through 3D bioprinting using the patient’s own cells, potentially eliminating the challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.

BIOLIFE4D is committed to perfecting the technology to make viable organ repair and replacement an accessible and affordable reality.

**World-Class Strategic Partnerships**

Strategic partnerships provide BIOLIFE4D access to and use of their core research facilities, equipment, and personnel expertise.



(Nasdaq: SAVU / SAVUW)

**BIOLIFE4D CORP.**

HQ: Buffalo Grove, IL  
**Leadership Team**  
 Chairman & CEO: Steven Morris  
 President: Kate Lewis  
 CFO: Wesley Ramjeet  
 CMO: Dr. Jeffrey Morgan

Auditors: LJ Solding Associates, LLC  
 Legal: FitzGerald Kreditor Bolduc Risbrough LLP;  
 Kaufman & Canoles, P.C.

**MARKET DATA**

Price <sup>1</sup>	\$x.xx
Market Cap <sup>1</sup>	\$xx.xM
Shares Outstanding <sup>1</sup>	xx.xM
Float <sup>1</sup>	xx.xM
Cash (proforma) <sup>2</sup>	\$3.5M

Fiscal Year: December 31

<sup>1</sup> as of May xx, 2023


<sup>2</sup> proforma cash includes gross proceeds from May 2023 IPO

[www.SAVUinfo.com](http://www.SAVUinfo.com)

**ADDRESSABLE MARKETS**

Each milestone in BIOLIFE4D’s proposed pipeline represents a unique commercialization opportunity completely independent of each other. Estimated markets which our technology may potentially address include:

- Human Mini-Heart: Testing **\$5B+**
- Cardiac Patch: Heart Repair **\$3B+**
- Vascular Graft: Heart Bypass **\$3B+**
- Heart Valves: Valve Replacement **\$8B+**
- Full-Size Human Heart: Transplantation **\$15B+**



RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at [www.sec.gov](http://www.sec.gov). BIOLIFE4D is a client of RedChip Companies, Inc. a \$7,500 monthly cash fee pre-IPO, \$12,500 post-IPO, and 6,000 shares of common stock, beginning in April 2022, for 6 months of RedChip investor awareness services. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services. This presentation includes forward-looking statements and is subject to risks; please review BIOLIFE4D's filings with the United States Securities and Exchange Commission available at: <http://www.sec.gov>. For a list of references, please visit [this site](http://this.site).



## COMPANY HIGHLIGHTS

### **Potentially addressing unmet needs in cardiovascular disease**

- Cardiovascular disease is the leading cause of death globally
- Due to lack of viable donor organs, only ~3500 heart transplants take place in the U.S. and ~5000 globally each year
- 2030 global cost of cardiac disease is set to rise to \$818 billion

### **Potential commercialization of human Mini-Heart in late 2023/2024**

- \$5B+ market opportunity
- Potentially provide a better predictive model than animal testing used for clinical trials; substantially reducing reliance on animal testing in pharma R&D
- No FDA approval currently required for initial commercialization of the Mini-Heart

### **Developing fully functioning 3D bioprinted heart**

- Potential to make viable organ repair and replacement an accessible and affordable reality
- Development path includes multiple milestones that each represent multiple independent market opportunities (cardiac patches; vascular grafts; heart valves)

### **World-class leadership and scientific team collaborating with world-class strategic partners**

- BIOLIFE4D utilizes Johnson & Johnson Innovation - JLABS, a premier life science incubator program
- Team with deep experience in life-sciences, biomedical engineering, tissue engineering, and transplantation

## VALUE PROPOSITION

BIOLIFE4D has a robust proposed product pipeline which includes cardiac patches, vascular grafts, heart valves, and a 3D bioprinted human heart. The Company expects to commercialize its first product, the Mini-Heart, in late 2023/ early 2024, targeting clinical research organizations and big pharma. The 3D bioprinted Mini-Heart is based on the geometry of a human heart and is being developed for potential use in cardiotoxicity testing in drug and vaccine development. Cardiotoxicity is frequently a major factor in failed human trials. The Mini-Heart potentially offers researchers a way to test drug candidates on a heart that is similar in form and function to a human heart, potentially providing a better predictive model than animal testing used for clinical trials, which could ultimately drive time and cost savings in the discovery phase for drug developers. No FDA approval is currently required to commercialize the Mini-Heart.

Ultimately, BIOLIFE4D is working toward the development of a patient-specific, fully functioning heart created through 3D bioprinting that uses a patient's own cells, which could potentially address the lack of supply of donor organs and could also improve some of the challenges associated with existing transplant methods, which include organ rejection and the need for extensive immunosuppressant therapy.

As BIOLIFE4D executes on its vision of perfecting the technology to make viable organ replacement an accessible and affordable reality, it is also working toward commercializing bioengineered cardiac components, such as cardiac valves and patches, that the Company believes will meaningfully impact patients with cardiovascular disease while BIOLIFE4D researchers continue development of a full-sized bioengineered human heart.